Extendicare (5XE) Stock Forecast & Price Target

0 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

5XE Analyst Ratings

Strong Buy

4 Buy

0 Hold

0 Sell

Based on 4 analysts giving stock ratings to

Extendicare

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

5XE Stock 12 Month Forecast

Average Price Target

€24.20

▲(24.75% Upside)

Based on 4 Wall Street analysts offering 12 month price targets for Extendicare in the last 3 months. The average price target is €24.20 with a high forecast of €24.82 and a low forecast of €23.58. The average price target represents a 24.75% change from the last price of €19.40.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6":"€6","25":"€25","10.75":"€10.75","15.5":"€15.5","20.25":"€20.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":24.821148,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€24.82</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":24.2006193,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€24.20</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":23.5800906,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€23.58</span>\n  </div></div>","useHTML":true}}],"tickPositions":[6,10.75,15.5,20.25,25],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,22.2,22.40162676923077,22.603253538461537,22.804880307692308,23.006507076923075,23.208133846153846,23.409760615384617,23.611387384615384,23.813014153846154,24.014640923076925,24.216267692307692,24.417894461538463,24.61952123076923,{"y":24.821148,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,22.2,22.35389379230769,22.507787584615382,22.661681376923077,22.81557516923077,22.96946896153846,23.123362753846152,23.277256546153847,23.43115033846154,23.58504413076923,23.73893792307692,23.892831715384617,24.046725507692308,{"y":24.2006193,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,22.2,22.306160815384615,22.41232163076923,22.518482446153847,22.62464326153846,22.730804076923075,22.83696489230769,22.943125707692307,23.049286523076923,23.15544733846154,23.261608153846154,23.367768969230767,23.473929784615382,{"y":23.5800906,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":7.57,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.888,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.894,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.558,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.145,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.664,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.273,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.185,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.815,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.429,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.75,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.174,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.2,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€24.82

Average Price Target€24.20

Lowest Price Target€23.58

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Pammi Bir

RBC Capital

€23.58→€24.2

Buy

24.75%

Upside

Reiterated

08/13/26

RBC Capital Sticks to Their Buy Rating for Extendicare (EXE)

Tom Callaghan

BMO Capital

€23.58

Buy

21.55%

Upside

Reiterated

08/10/26

Extendicare Maintained at Buy as Solid Results and Growth Outlook Support Unchanged $38 Price Target

Tal Woolley

CIBC

€23.58→€24.82

Buy

27.94%

Upside

Reiterated

08/10/26

Extendicare (EXE) Gets a Buy from CIBC

Jonathan Kelcher

TD Cowen

€24.2

Buy

24.75%

Upside

Reiterated

08/09/26

Analyst Reiterates Buy Rating and Maintains Target Price on Expected AFFO Growth and Home Health Care Recovery

Unknown Analyst

ATB Cormark Capital Markets

Not Ranked

ATB Cormark Capital Markets

€21.72→€26.68

Buy

37.54%

Upside

Reiterated

05/11/26

Extendicare (EXE) Receives a Buy from ATB Cormark Capital Markets

Lorne Kalmar

Desjardins

€21.41

Buy

10.35%

Upside

Initiated

04/22/26

Extendicare initiated with a Buy at DesjardinsExtendicare initiated with a Buy at Desjardins

Tania Armstrong-Whitworth

Canaccord Genuity

€12.41→€13.96

Buy

-28.03%

Downside

Reiterated

12/04/25

Canaccord Genuity Sticks to Their Buy Rating for Extendicare (EXE)

Giuliano Thornhill

National Bank

€13.34→€15.2

Buy

-21.63%

Downside

Reiterated

12/04/25

Extendicare price target raised to C$24.50 from C$21.50 at National BankExtendicare price target raised to C$24.50 from C$21.50 at National Bank

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Pammi Bir

RBC Capital

€23.58→€24.2

Buy

24.75%

Upside

Reiterated

08/13/26

RBC Capital Sticks to Their Buy Rating for Extendicare (EXE)

Tom Callaghan

BMO Capital

€23.58

Buy

21.55%

Upside

Reiterated

08/10/26

Extendicare Maintained at Buy as Solid Results and Growth Outlook Support Unchanged $38 Price Target

Tal Woolley

CIBC

€23.58→€24.82

Buy

27.94%

Upside

Reiterated

08/10/26

Extendicare (EXE) Gets a Buy from CIBC

Jonathan Kelcher

TD Cowen

€24.2

Buy

24.75%

Upside

Reiterated

08/09/26

Analyst Reiterates Buy Rating and Maintains Target Price on Expected AFFO Growth and Home Health Care Recovery

Unknown Analyst

ATB Cormark Capital Markets

Not Ranked

ATB Cormark Capital Markets

€21.72→€26.68

Buy

37.54%

Upside

Reiterated

05/11/26

Extendicare (EXE) Receives a Buy from ATB Cormark Capital Markets

Lorne Kalmar

Desjardins

€21.41

Buy

10.35%

Upside

Initiated

04/22/26

Extendicare initiated with a Buy at DesjardinsExtendicare initiated with a Buy at Desjardins

Tania Armstrong-Whitworth

Canaccord Genuity

€12.41→€13.96

Buy

-28.03%

Downside

Reiterated

12/04/25

Canaccord Genuity Sticks to Their Buy Rating for Extendicare (EXE)

Giuliano Thornhill

National Bank

€13.34→€15.2

Buy

-21.63%

Downside

Reiterated

12/04/25

Extendicare price target raised to C$24.50 from C$21.50 at National BankExtendicare price target raised to C$24.50 from C$21.50 at National Bank

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

ODTXOdyssey Therapeutics, Inc.

BTSGBrightSpring Health Services, Inc.

GPCRStructure Therapeutics, Inc. Sponsored ADR

AMLXAmylyx Pharmaceuticals Inc

IMMXImmix Biopharma

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Extendicare

3 Months

PerPlexity Health Care CATipRanks - PerPlexity

Success Rate

2/4 ratings generated profit

Average Return

+8.40%

Copying PerPlexity Health Care CA's trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of +8.40% per trade.

1 Year

PerPlexity Health Care CATipRanks - PerPlexity

Success Rate

2/4 ratings generated profit

Average Return

+15.20%

Copying PerPlexity Health Care CA's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +15.20% per trade.

2 Years

PerPlexity Health Care CATipRanks - PerPlexity

Success Rate

2/4 ratings generated profit

Average Return

+15.20%

Copying PerPlexity Health Care CA's trades and holding each position for 2 Years would result in 50.00% of your transactions generating a profit, with an average return of +15.20% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

5XE Analyst Recommendation Trends

Rating

Apr 26

May 26

Jun 26

Jul 26

Aug 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 5XE has received 4 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. 5XE average Analyst price target in the past 3 months is 24.20.

Each month's total comprises the sum of three months' worth of ratings.

5XE Financial Forecast

5XE Earnings Forecast

Next quarter’s earnings estimate for 5XE is €0.23 with a range of €0.23 to €0.23. The previous quarter’s EPS was €0.20. 5XE beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 5XE has Performed in-line its overall industry.

5XE Sales Forecast

Next quarter’s sales forecast for 5XE is €373.78M with a range of €370.50M to €377.05M. The previous quarter’s sales results were €380.29M. 5XE beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 5XE has Performed in-line its overall industry.

5XE Stock Forecast FAQ

What is DE:5XE’s average 12-month price target, according to analysts?

Based on analyst ratings, Extendicare’s 12-month average price target is 24.20.

What is DE:5XE’s upside potential, based on the analysts’ average price target?

Extendicare has 24.75% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Extendicare a Buy, Sell or Hold?

Extendicare has a consensus rating of Strong Buy, which is based on 4 buy ratings, 0 hold ratings and 0 sell ratings.

What is Extendicare’s share price target?

The average share price target for Extendicare is 24.20. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €24.82 ,and the lowest forecast is €23.58. The average share price target represents 24.75% Increase from the current price of €19.4.

What do analysts say about Extendicare?

Extendicare’s analyst rating consensus is a Strong Buy. This is based on the ratings of 4 Wall Streets Analysts.

How can I buy shares of Extendicare?

To buy shares of DE:5XE, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Extendicare (5XE) Stock Forecast & Price Target

5XE Analyst Ratings

5XE Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Extendicare

5XE Analyst Recommendation Trends

5XE Financial Forecast

5XE Earnings Forecast

5XE Sales Forecast

5XE Stock Forecast FAQ

Detailed List of Analyst Forecasts